Ua ʻae ʻia ʻo Pembrolizumab ma Kina no ka HCC hiki ʻole ke ʻoki ʻia i ka hui pū ʻana me Lenvatinib a me TACE

I kēia mau lā aku nei, ua hoʻolaha ʻo Merck & Co., Inc. (Merck) ua ʻāpono ʻia kāna mea hoʻopaʻa PD-1, ʻo pembrolizumab, e ka National Medical Products Administration (NMPA) o Kina no ka hoʻohana ʻana me ka lenvatinib a me ka transarterial chemoembolization (TACE) no ka mālama ʻana i nā maʻi me ka hepatocellular carcinoma hiki ʻole ke hoʻopau ʻia, non-metastatic.

Ua hoʻokumu ʻia ka ʻae ʻia ʻana o kēia hōʻailona hou ma ka ʻikepili mai ka hoʻokolohua lapaʻau Phase III LEAP-012. Ma kēia haʻawina Phase III multicenter, randomized, double-blind (LEAP-012), ua kākau inoa ʻia he 480 mau maʻi a ua hoʻonohonoho ʻia ma ke ʻano random e loaʻa iā lenvatinib me TACE me pembrolizumab (n=237) a i ʻole TACE me dual placebo (n=243).

Ua hōʻike ʻia nā hopena ʻo ka awelika o ke ola ʻole o ka holomua (PFS) he 14.6 mau mahina ma ka hui lenvatinib me TACE me pembrolizumab, i hoʻohālikelike ʻia me 10.0 mau mahina ma ka hui placebo. ʻO nā helu ola holoʻokoʻa (OS) 24 mahina he 75% a me 69%, kēlā me kēia.

ʻO Lenvatinibhe mea hoʻopaʻa kinase i hoʻohana ʻia e mālama i kekahi mau ʻano maʻi kanesa. ʻO nā mea hoʻopaʻa kinase he mau mea hoʻopaʻa enzyme e ālai ana i ka hana o hoʻokahi a ʻoi aku paha nā kinase protein.

ʻO Pembrolizumab kahi antibody IgG4 kappa monoclonal humanized i kuhikuhi ʻia i ka ʻili o ke kelepona kanaka PD-1 (programmed death receptor-1) ma nā lymphocytes. Hāʻawi ka receptor PD-1 i kahi "checkpoint immune" koʻikoʻi, e kōkua ana i ka pale ʻana i ka ʻōnaehana pale mai ka hoʻouka ʻana iā ia iho. Loaʻa i kekahi mau ʻano tumors kahi hōʻike kiʻekiʻe o PD-L1 (programmed death receptor ligand-1). Hoʻohana nā ʻano tumors ʻē aʻe i ke kū'ē ʻana o ka immune adaptive kahi e lawe ai lākou i ke physiology kūlohelohe o ka PD-L1 induction (pale ʻana i ka pōʻino i hoʻopili ʻia e ka immune mai nā maʻi) a hoʻololi iā ia i nā pane anti-tumor. Ke hui pū ʻo PD-L1 me PD-1, ua kāohi ʻia ka hana T-cell; pale ʻo pembrolizumab i ka hoʻokumu ʻana o ka PD-1: PDL-1 e ʻae ana i ka pepehi ʻana i hoʻopili ʻia e T-cell.

I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.

Helu Kelepona：4008803716

Email：myimmnet@163.com